Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Longeveron Inc. (LGVN : NSDQ)
 
 • Company Description   
Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.

Number of Employees: 22

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.19 Daily Weekly Monthly
20 Day Moving Average: 548,569 shares
Shares Outstanding: 20.91 (millions)
Market Capitalization: $171.27 (millions)
Beta: -2.02
52 Week High: $45.00
52 Week Low: $2.84
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.74% -27.45%
12 Week 32.52% 48.94%
Year To Date -32.15% -17.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1951 NW 7TH AVENUE SUITE 520
-
MIAMI,FL 33136
USA
ph: 305-909-0840
fax: -
investorrelations@longeveron.com http://www.longeveron.com
 
 • General Corporate Information   
Officers
Geoff Green - Chief Executive Officer
Joshua M. Hare - Chairman and Director
James Clavijo - Chief Financial Officer and Treasurer
Paul Lehr - General Counsel and Secretary
Donald M. Soffer - Director

Peer Information
Longeveron Inc. (CORR.)
Longeveron Inc. (RSPI)
Longeveron Inc. (CGXP)
Longeveron Inc. (BGEN)
Longeveron Inc. (GTBP)
Longeveron Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 54303L104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 20.91
Most Recent Split Date: (:1)
Beta: -2.02
Market Capitalization: $171.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.99
Price/Cash Flow: -
Price / Sales: 131.75
EPS Growth
vs. Year Ago Period: 5.56%
vs. Previous Quarter: 15.00%
Sales Growth
vs. Year Ago Period: -1.60%
vs. Previous Quarter: 77.03%
ROE
03/31/22 - -58.76
12/31/21 - -61.46
09/30/21 - -75.99
ROA
03/31/22 - -50.22
12/31/21 - -51.57
09/30/21 - -58.09
Current Ratio
03/31/22 - 13.28
12/31/21 - 13.06
09/30/21 - 10.18
Quick Ratio
03/31/22 - 13.28
12/31/21 - 13.06
09/30/21 - 10.18
Operating Margin
03/31/22 - -1,341.85
12/31/21 - -1,305.13
09/30/21 - -629.34
Net Margin
03/31/22 - -1,341.85
12/31/21 - -1,305.13
09/30/21 - -629.34
Pre-Tax Margin
03/31/22 - -1,341.85
12/31/21 - -1,305.13
09/30/21 - -629.34
Book Value
03/31/22 - 1.64
12/31/21 - 1.79
09/30/21 - 1.17
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.64
 

Powered by Zacks Investment Research ©